Multiple Myeloma Diagnosis Market Size, Share, Growth, and Industry Analysis, By Type (Routine IVD Testing, Clinical Trials), By Application (Pharmaceutical Company, Medical Labs, Academic & Medical Schools, Others), Regional Insights and Forecast to 2035

•   
•   
  

  Download Free Sample to learn more about this report

    

MULTIPLE MYELOMA DIAGNOSIS MARKET OVERVIEW

The global Multiple Myeloma Diagnosis Market size estimated at USD 35.75 billion in 2026 and is projected to reach USD 106.35 billion by 2035, growing at a CAGR of 12.88% from 2026 to 2035.

The Multiple Myeloma Diagnosis Market is expanding due to rising hematologic cancer screening rates, increasing laboratory automation, and wider adoption of molecular diagnostic technologies. More than 187,000 new multiple myeloma cases were recorded globally in 2024, while over 114,000 deaths were associated with plasma cell malignancies. Bone marrow biopsy testing accounts for nearly 41% of diagnostic procedures, while serum protein electrophoresis contributes close to 29% of total testing demand. Hospital laboratories perform over 58% of diagnostic workflows globally. Flow cytometry utilization increased by 33% across oncology laboratories during 2024. Diagnostic sensitivity for next-generation sequencing tests reached 94% in advanced disease detection applications across specialized oncology centers.

The United States represents the largest contributor to the Multiple Myeloma Diagnosis Market due to strong oncology infrastructure and high screening adoption. More than 36,000 new multiple myeloma cases were diagnosed in the U.S. during 2024, with adults above 65 years accounting for nearly 61% of total cases. Clinical laboratories in the country processed over 8.4 million hematology diagnostic tests linked to plasma cell disorders during 2024. Immunofixation electrophoresis utilization increased by 27% across cancer centers, while advanced genomic testing adoption crossed 39% in tertiary hospitals. More than 72% of U.S. oncology hospitals integrated automated diagnostic analyzers for early-stage myeloma identification and disease progression monitoring.

KEY FINDINGS

LATEST TRENDS

The Multiple Myeloma Diagnosis Market is witnessing substantial transformation through integration of molecular diagnostics, digital pathology, and artificial intelligence-driven interpretation systems. More than 63% of oncology hospitals introduced automated hematology analyzers during 2024 to improve diagnostic precision and reduce turnaround time. Next-generation sequencing adoption increased by 34% in cancer diagnostic centers, while fluorescence in situ hybridization testing utilization expanded by 28% globally. Minimal residual disease testing penetration crossed 37% across specialized oncology clinics due to rising emphasis on early relapse detection.

Liquid biopsy testing is emerging as a significant trend, with adoption increasing by 26% in hematologic malignancy monitoring applications. Multiparameter flow cytometry continues to dominate laboratory-based diagnosis, accounting for nearly 44% of advanced diagnostic workflows globally. Automated immunoassay systems reduced laboratory processing time by 31%, improving clinical efficiency across tertiary care facilities. Digital pathology integration in oncology laboratories increased by 22%, while cloud-based laboratory information systems expanded by 35% in diagnostic centers.

MARKET DYNAMICS

Driver

Rising demand for early cancer detection and precision diagnostics.

The increasing global prevalence of hematologic malignancies continues to accelerate demand for advanced multiple myeloma diagnostic technologies. More than 187,000 new cases were reported worldwide during 2024, while nearly 61% of diagnosed patients were aged above 65 years. Early-stage detection improved survival outcomes by 47%, encouraging hospitals and oncology laboratories to expand screening programs. Flow cytometry adoption increased by 33% globally because of its ability to identify abnormal plasma cells with high sensitivity.

Restraint

High diagnostic equipment costs and reimbursement limitations.

Advanced molecular diagnostic systems and genomic analyzers require substantial capital investment, limiting adoption among smaller healthcare facilities. More than 42% of independent diagnostic laboratories reported delayed procurement of automated testing systems due to high equipment costs. Reimbursement coverage limitations affected approximately 37% of specialized myeloma diagnostic procedures globally during 2024. Maintenance costs for next-generation sequencing platforms increased by 18%, while skilled pathology workforce shortages reduced operational efficiency by 29% in emerging healthcare markets.

Expansion of personalized medicine and genomic profiling technologies

Opportunity

The increasing adoption of precision oncology creates substantial growth opportunities for advanced multiple myeloma diagnostic solutions. More than 41% of hematologic cancer clinical trials incorporated biomarker-based patient selection during 2024. Genomic sequencing utilization expanded by 34%, while minimal residual disease testing adoption increased by 27% globally.

Pharmaceutical companies invested heavily in companion diagnostic collaborations, supporting targeted therapy development and personalized treatment strategies.

Complexity of disease diagnosis and variability in testing standards

Challenge

Multiple myeloma diagnosis involves numerous laboratory procedures including serum electrophoresis, bone marrow biopsy, imaging, and molecular profiling, creating workflow complexity across healthcare systems. More than 32% of laboratories reported inconsistencies in biomarker interpretation standards during 2024.

Variability in sample preparation procedures affected testing accuracy by nearly 18% across decentralized laboratories. Diagnostic turnaround time exceeded 7 days in approximately 36% of regional hospitals due to limited automation and specialist shortages.

•   
•   
  

  Download Free Sample to learn more about this report

    

MULTIPLE MYELOMA DIAGNOSIS MARKET SEGMENTATION

By Type

• Routine IVD Testing: Routine IVD testing represents the largest segment within the Multiple Myeloma Diagnosis Market, accounting for nearly 67% of global testing demand during 2024. Serum protein electrophoresis remains one of the most widely used procedures, contributing approximately 34% of routine hematology testing workflows. Immunofixation testing utilization increased by 27% globally due to rising requirements for monoclonal protein detection. Hospital laboratories perform over 58% of routine multiple myeloma diagnostic procedures, while automated analyzers reduced laboratory processing time by 31%.

• Clinical Trials: Clinical trial diagnostics account for nearly 33% of the Multiple Myeloma Diagnosis Market due to increasing precision oncology research activities. More than 41% of ongoing hematologic cancer clinical trials incorporated genomic profiling during 2024. Minimal residual disease testing adoption within clinical trials increased by 29%, while biomarker-driven patient enrollment procedures expanded by 24%. Pharmaceutical research collaborations with diagnostic companies increased by 21%, accelerating development of companion diagnostic assays.

By Application

• Pharmaceutical Company: Pharmaceutical companies account for approximately 38% of application demand within the Multiple Myeloma Diagnosis Market due to increasing targeted therapy development. More than 46% of pharmaceutical oncology programs incorporated companion diagnostics during 2024. Biomarker screening utilization increased by 28% in hematologic cancer drug development activities, while genomic sequencing adoption expanded by 34%. Clinical trial enrollment supported by molecular diagnostic testing rose by 22% globally.

• Medical Labs: Medical laboratories contribute nearly 31% share of the Multiple Myeloma Diagnosis Market because of rising hematology testing volumes and increasing automation adoption. More than 8.4 million plasma cell disorder diagnostic procedures were processed globally during 2024 across independent and hospital-affiliated laboratories. Automated immunoassay systems reduced diagnostic turnaround time by 26%, while flow cytometry integration increased by 33%. Serum free light chain testing utilization exceeded 52% across specialized hematology laboratories.

• Academic & Medical Schools: Academic and medical schools represent approximately 19% share of the Multiple Myeloma Diagnosis Market due to increasing oncology research activities and educational investments. More than 3,800 hematologic cancer studies were conducted globally during 2024, while research funding for plasma cell disorder diagnostics increased by 23%. Genomic sequencing utilization within academic institutes expanded by 31%, supporting biomarker discovery and precision medicine development. Approximately 44% of oncology training hospitals integrated advanced flow cytometry platforms into laboratory education programs.

• Others: Other applications including specialty oncology clinics, independent diagnostic centers, and community healthcare providers account for nearly 12% of market demand. Specialty clinics increased adoption of portable diagnostic analyzers by 17% during 2024 to improve accessibility in decentralized healthcare environments. Telepathology implementation expanded by 19%, enabling remote diagnostic consultation for hematologic malignancies. Independent cancer centers contributed approximately 26% of outpatient diagnostic procedures globally.

•   
•   
  Download Free Sample to learn more about this report

    

MULTIPLE MYELOMA DIAGNOSIS MARKET REGIONAL OUTLOOK

• North America

North America holds approximately 43% share of the Multiple Myeloma Diagnosis Market due to advanced healthcare infrastructure, widespread cancer screening programs, and high adoption of molecular diagnostics. The United States accounts for nearly 81% of regional testing volumes, while Canada contributes 14% through expanding oncology laboratory investments.

More than 36,000 new multiple myeloma cases were diagnosed in the United States during 2024, increasing demand for precision diagnostic solutions. Flow cytometry utilization exceeded 61% across tertiary oncology centers, while genomic sequencing adoption increased by 34% in hematologic cancer diagnosis.

• Europe

Europe accounts for nearly 29% of the Multiple Myeloma Diagnosis Market due to strong public healthcare systems and high oncology research spending. Germany, France, the United Kingdom, and Italy collectively contribute over 68% of regional testing demand. More than 48,000 multiple myeloma cases were recorded across Europe during 2024, supporting increased laboratory testing volumes.

Flow cytometry penetration reached 52% in regional oncology hospitals, while serum protein electrophoresis remained widely utilized in over 74% of hematology laboratories. Genomic sequencing adoption increased by 26% across European cancer research institutes during 2024. Automated pathology systems improved laboratory productivity by 24%, while digital healthcare integration expanded by 31% across diagnostic facilities.

• Asia-Pacific

Asia-Pacific represents approximately 21% of the Multiple Myeloma Diagnosis Market and is experiencing strong growth due to increasing healthcare investments and rising cancer awareness. China, Japan, India, and South Korea collectively account for nearly 73% of regional diagnostic demand. More than 61,000 multiple myeloma cases were diagnosed across Asia-Pacific during 2024, while aging populations significantly increased hematologic cancer screening volumes.

Hospital automation adoption increased by 28%, improving diagnostic workflow efficiency in urban healthcare facilities. Flow cytometry utilization expanded by 31% across oncology hospitals, while genomic sequencing adoption increased by 29% in specialized cancer institutes. Government investments in public healthcare infrastructure improved access to advanced hematology diagnostics across major metropolitan regions.

• Middle East & Africa

Middle East & Africa account for nearly 7% of the Multiple Myeloma Diagnosis Market due to expanding healthcare modernization initiatives and increasing oncology infrastructure investments. Saudi Arabia, the United Arab Emirates, and South Africa collectively contribute approximately 58% of regional testing demand. More than 14,000 multiple myeloma cases were diagnosed across the region during 2024, increasing demand for specialized hematology diagnostic services.

Government healthcare expenditure on cancer diagnostics increased by 17% across major Gulf economies. Flow cytometry penetration reached 28% in tertiary hospitals, while laboratory automation adoption improved by 21% during 2024. Public-private healthcare partnerships supported installation of advanced pathology analyzers in regional oncology centers.

LIST OF TOP MULTIPLE MYELOMA DIAGNOSIS COMPANIES

• Danaher Corporation
• Becton, Dickinson and Company
• Bio-Rad Laboratories, Inc.
• bioMérieux S.A.
• Parexel
• SkylineDx
• Sysmex Corporation
• Abbott Laboratories
• Bioclinica
• DiaSorin S.p.A.
• Siemens Healthcare
• Thermo Fisher Scientific Inc
• Sebia
• Ortho Clinical Diagnostics

List Of Top 2 Companies Market Share

• Danaher Corporation held approximately 16% share in the global multiple myeloma diagnosis industry during 2024 due to strong molecular diagnostics and flow cytometry product portfolios.
• Thermo Fisher Scientific Inc accounted for nearly 13% market share supported by extensive genomic sequencing platforms and oncology diagnostic reagent distribution networks.

INVESTMENT ANALYSIS AND OPPORTUNITIES

Investment activity in the Multiple Myeloma Diagnosis Market increased substantially during 2024 due to rising demand for precision oncology and automated laboratory systems. Global oncology diagnostic infrastructure investments expanded by 27%, while genomic sequencing laboratory installations increased by 24%. More than 41% of hematologic oncology clinical trials incorporated biomarker-based testing procedures, encouraging pharmaceutical companies to invest in companion diagnostic development partnerships. Venture capital funding in molecular pathology startups increased by 19%, supporting innovation in liquid biopsy and AI-assisted diagnostic technologies.

Hospital modernization programs improved adoption of digital pathology platforms by 22%, while laboratory automation investments expanded by 31% across tertiary healthcare facilities. Emerging economies increased oncology screening budgets by 18%, creating opportunities for diagnostic manufacturers to expand regional operations. Telepathology integration grew by 16%, improving accessibility to specialized hematology diagnostics in remote areas.

NEW PRODUCT DEVELOPMENT

New product development in the Multiple Myeloma Diagnosis Market is focused on molecular diagnostics, AI-assisted pathology systems, and high-sensitivity testing platforms. More than 24% of newly launched oncology diagnostic products during 2024 included genomic profiling capabilities. Automated flow cytometry analyzers improved plasma cell detection sensitivity by 32%, while next-generation sequencing platforms reduced diagnostic processing time by 26%.

Liquid biopsy innovation expanded significantly, with adoption of circulating tumor DNA testing increasing by 21% in hematologic malignancy monitoring applications. Artificial intelligence-powered pathology software improved interpretation accuracy by 29% across pilot oncology laboratories. Diagnostic reagent manufacturers introduced high-throughput immunoassay kits capable of processing over 1,200 samples daily in centralized laboratories.

FIVE RECENT DEVELOPMENTS (2023-2025)

• In 2025, Danaher Corporation expanded automated flow cytometry deployment capacity by 23% across oncology laboratories to improve plasma cell disorder testing efficiency.
• In 2024, Thermo Fisher Scientific Inc launched advanced genomic sequencing panels capable of increasing mutation detection sensitivity by 31% for hematologic malignancies.
• In 2024, Sysmex Corporation introduced upgraded hematology analyzers with 28% faster sample processing performance for oncology diagnostic laboratories.
• In 2023, Sebia improved immunofixation electrophoresis testing accuracy by 19% through development of enhanced protein separation technologies.
• In 2025, Abbott Laboratories expanded AI-integrated pathology software deployment by 22% to strengthen hematologic cancer screening efficiency across hospital laboratories.

MULTIPLE MYELOMA DIAGNOSIS MARKET REPORT COVERAGE

The Multiple Myeloma Diagnosis Market report covers diagnostic technologies, testing procedures, application areas, competitive landscape, and regional performance across major healthcare economies. The report analyzes more than 14 leading diagnostic manufacturers and evaluates utilization trends for flow cytometry, serum electrophoresis, immunoassays, genomic sequencing, and bone marrow pathology testing. Over 65% of report coverage focuses on advanced molecular diagnostic technologies and automation trends shaping oncology laboratory modernization.

The study evaluates diagnostic adoption patterns across pharmaceutical companies, medical laboratories, academic institutes, and specialty oncology centers. Regional analysis covers North America, Europe, Asia-Pacific, and Middle East & Africa, representing over 95% of global hematology diagnostic activity. More than 120 quantitative data points related to testing penetration, screening rates, hospital automation, and biomarker adoption are included within the report scope.